Skip to main content
. 2016 Jan 11;29(1):32–48. doi: 10.1016/j.ccell.2015.12.007

Figure 7.

Figure 7

Schematic Diagram Summarizes Aberrant Epigenetic Networks and Therapeutic Potentials of Targeting PRMT1 and KDM4C in AML

Left panel indicates the aberrant recruitment of PRMT1 and KDM4C by MLL fusions and MOZ-TIF2 to drive oncogenic transcriptional programs. Panels on the right depict the potential targeting of epigenetic modifying enzymes for leukemia suppression. MLL fusions in the diagram refer to MLL-GAS7 and MLL-EEN, although KDM4C inhibition can also be effective for other MLL fusions including MLL-AF9.